البروفيسور نيلز ثوينيسن هو متخصص دولي في أمراض السرطان والأمراض التنكسية المزمنة والطب التجديدي مع أكثر من 20 عامًا من الخبرة في الطب القائم على الأدلة و 14 عامًا من الخبرة السريرية في العلاج بالدم. قام بتأليف 40 منشورًا علميًا في مجلات علمية محكمة وحصل على 6 جوائز. تلقى تدريبًا بعد التخرج في جامعة مونستر ، وكلية الطب بجامعة كارديف ، وجامعة ماينز ، ومركز سيدارز سيناء الطبي. يشغل حاليًا منصب المدير الطبي لـ CBC Health ، وشغل مناصب سابقة كرئيس للأطباء في مستشفى سانت جورج ، ومركز كلوستر باراديس الطبي ، والمركز الطبي الجامعي هامبورغ-إيبندورف.
Accommodation is not included
نقل المطار والعيادة والمطار
CBC Health is a day-clinic where the patient will get his treatment and will be released every day to the hotel.
Symptoms after a stroke: cord blood and stem cells prove their curative effect.
According to statistics, 20 to 25% of patients who survive a stroke die within the following four weeks. All others have various degrees of brain damage, ranging from mild problems in everyday life to severe symptoms requiring long-term care. Is there a way to avoid this? New methods of regenerative therapy suggest that there is.
Umbilical cord blood - therapies and stem cells for a better prognosis
As a result of a stroke, there is reactive inflammation in the brain caused by the damaged tissue. Unfortunately, this impairs the patient's recovery process and can also affect adjacent healthy brain tissue.
Here, recent meta-analyses in the field of regenerative medicine from 2022 show that it is possible to optimize prognosis after stroke has occurred (Paton MCB et al, Cytotherapy, 2022). Intravenous delivery of umbilical cord blood (UCB) may lead to improvement in this case, as the primitive cells contained in UCB may help inflammation in the brain to subside more quickly and rescue neurons that are about to die. In addition, UCB provides powerful growth factors and molecules that stimulate natural healing processes such as the formation of new synapses and neuronal circuitry.
While the efficacy of regenerative stem cell therapy has not been fully researched, there are no concerns about unexpected safety risks associated with its use. Most positively, there are no reports of immunological rejection, and UCB has an even lower risk profile than traditional blood transfusion in adults. These findings give stroke patients reason to hope for a better future.
منسق طبي خاص
ترتيبات السفر الطبي - حجز تذاكر السفر الجوي وغرف الفنادق بأسعار خاصة للشركاء
دعوة المريض أثناء السفر الطبي